Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients

被引：1
|
作者：
Gorgulho, Joao [1 ]
von Felden, Johann [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Gastroenterol & Hepatol, Hamburg, Germany
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
关键词：
D O I：
10.1111/apt.18296
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1467 / 1468
页数：2
相关论文
共 50 条
  • [31] Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)
    Sarker, Debashis
    Borek, Weronika E.
    Pedicona, Federico
    Zen, Yoh
    Christopher, Josie A.
    Karampera, Christina
    Campbell, Amy
    Khorsandi, Shirin Elizabeth
    Dowe, Thomas
    Habarwaa, Marwo
    Britton, David James
    Heaton, Nigel
    Cutillas, Pedro Rodriguez
    Williamson, Andrew
    Dokal, Arran David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Morishita, Asahiro
    Okamoto, Koichi
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Masaki, Tsutomu
    Takayama, Tetsuji
    CANCERS, 2023, 15 (21)
  • [33] External beam radiation therapy improves the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombosis
    Lee, Yunjeong
    Kim, Jin-Wook
    JOURNAL OF HEPATOLOGY, 2024, 80 : S450 - S450
  • [34] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [35] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy (vol 52, pg 298, 2022)
    Maesaka, K.
    Sakamori, R.
    Yamada, R.
    Tahata, Y.
    Imai, Y.
    Ohkawa, K.
    HEPATOLOGY RESEARCH, 2022, 52 (07) : 659 - 659
  • [36] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Reika Yamauchi
    Takanori Ito
    Sachiyo Yoshio
    Takafumi Yamamoto
    Kazuyuki Mizuno
    Masatoshi Ishigami
    Hiroki Kawashima
    Satoshi Yasuda
    Shigeo Shimose
    Hideki Iwamoto
    Taiji Yamazoe
    Taizo Mori
    Eiji Kakazu
    Takumi Kawaguchi
    Hidenori Toyoda
    Tatsuya Kanto
    Journal of Gastroenterology, 2023, 58 : 565 - 574
  • [37] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Yamauchi, Reika
    Ito, Takanori
    Yoshio, Sachiyo
    Yamamoto, Takafumi
    Mizuno, Kazuyuki
    Ishigami, Masatoshi
    Kawashima, Hiroki
    Yasuda, Satoshi
    Shimose, Shigeo
    Iwamoto, Hideki
    Yamazoe, Taiji
    Mori, Taizo
    Kakazu, Eiji
    Kawaguchi, Takumi
    Toyoda, Hidenori
    Kanto, Tatsuya
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (06) : 565 - 574
  • [38] Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
    Ando, Yuwa
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Johira, Yusuke
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Kosaka, Yumi
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Okamoto, Wataru
    Takahashi, Shoichi
    Imamura, Michio
    Chayama, Kazuaki
    Aikata, Hiroshi
    CANCERS, 2021, 13 (16)
  • [39] Prediction of treatment response using contrast-enhanced ultrasonography in patients treated with Atezolizumab and Bevacizumab for unresectable hepatocellular carcinoma
    Takada, Hitomi
    Maekawa, Shinya
    Enomoto, Nobuyuki
    JOURNAL OF HEPATOLOGY, 2022, 77 : S387 - S387
  • [40] Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma
    Ascari, S.
    Chen, R.
    Iavarone, M.
    Stefanini, B.
    Marra, F.
    Cabibbo, G.
    Vivaldi, C.
    Palloni, A.
    Solda, C.
    Ponziani, F. R.
    Valenzi, E.
    Ravaioli, F.
    Franceschini, E.
    Tosetti, G.
    Campani, C.
    Celsa, C.
    Masi, G.
    Brandi, G.
    Lonardi, S.
    Stella, L.
    Pressiani, T.
    Lani, L.
    Dalbeni, A.
    Svegliati-Baroni, G.
    Federico, P.
    Ielasi, L.
    De Lorenzo, S.
    Piscaglia, F.
    Tovoli, F.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
12345